Platelet recruitment to venous stent thrombi

Robert D. McBane, Krzysztof Karnicki, Waldemar E. Wysokinski

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Thrombosis following venous stent placement is a morbid clinical outcome. Whether to target platelets or coagulation factors for venous stent thromboprophylaxis remains unclear. We sought to determine whether integrin αIIbβ3 antagonism with lamifiban would inhibit platelet recruitment to venous stent thrombosis. Anti-thrombotic efficacy was compared between venous and arterial circulations. Pigs received either lamifiban (0.2 mg/kg bolus plus 0.2 mg/kg/h infusion; n = 6) or saline (n = 12). Carotid arteries were crush injured and then harvested 30 min later to provide an assessment of antithrombotic efficacy in the arterial circulation. Iliac venous stents were then deployed and thrombi allowed to propagate for 2 h before harvesting. Platelet deposition was measured by scintillation detection of autologous 111In-platelets. Venous thrombi were quantified by weight and compared to platelet, Von Willebrand factor (VWF) and fibrinogen content. Arterial platelet deposition (×106/cm2) was reduced >80 % by lamifiban (398 ± 437) compared to controls (1,540 ± 883; p < 0.005). Lamifiban also reduced venous thrombus platelet deposition (139 ± 88 vs. 281 ± 167) however did not prevent thrombosis. In control animals, venous stent platelet deposition correlated with plasma fibrinogen content (R2 = 0.29; p = 0.03). Fibrinogen content correlated directly with venous stent platelet deposition (p = 0.03) but not thrombus weight. Neither venous platelet deposition nor thrombus weights varied by VWF content. Platelet recruitment to venous stent thrombi occurs in part through the integrin αIIbβ3 receptor. Unlike arterial thrombosis, inhibition of this receptor is insufficient to prevent venous stent thrombosis.

Original languageEnglish (US)
Pages (from-to)442-447
Number of pages6
JournalJournal of Thrombosis and Thrombolysis
Volume36
Issue number4
DOIs
StatePublished - Nov 2013

Fingerprint

Stents
Thrombosis
Blood Platelets
Venous Thrombosis
Fibrinogen
von Willebrand Factor
Weights and Measures
Integrins
Blood Coagulation Factors
Carotid Arteries
Swine
lamifiban

Keywords

  • GP IIb/IIIa
  • Integrin αIIbβ3
  • Lamifiban
  • Platelets
  • Venous stent thrombosis

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Platelet recruitment to venous stent thrombi. / McBane, Robert D.; Karnicki, Krzysztof; Wysokinski, Waldemar E.

In: Journal of Thrombosis and Thrombolysis, Vol. 36, No. 4, 11.2013, p. 442-447.

Research output: Contribution to journalArticle

McBane, RD, Karnicki, K & Wysokinski, WE 2013, 'Platelet recruitment to venous stent thrombi', Journal of Thrombosis and Thrombolysis, vol. 36, no. 4, pp. 442-447. https://doi.org/10.1007/s11239-013-0924-x
McBane, Robert D. ; Karnicki, Krzysztof ; Wysokinski, Waldemar E. / Platelet recruitment to venous stent thrombi. In: Journal of Thrombosis and Thrombolysis. 2013 ; Vol. 36, No. 4. pp. 442-447.
@article{1953bd0b496941629149537dffa4ce7d,
title = "Platelet recruitment to venous stent thrombi",
abstract = "Thrombosis following venous stent placement is a morbid clinical outcome. Whether to target platelets or coagulation factors for venous stent thromboprophylaxis remains unclear. We sought to determine whether integrin αIIbβ3 antagonism with lamifiban would inhibit platelet recruitment to venous stent thrombosis. Anti-thrombotic efficacy was compared between venous and arterial circulations. Pigs received either lamifiban (0.2 mg/kg bolus plus 0.2 mg/kg/h infusion; n = 6) or saline (n = 12). Carotid arteries were crush injured and then harvested 30 min later to provide an assessment of antithrombotic efficacy in the arterial circulation. Iliac venous stents were then deployed and thrombi allowed to propagate for 2 h before harvesting. Platelet deposition was measured by scintillation detection of autologous 111In-platelets. Venous thrombi were quantified by weight and compared to platelet, Von Willebrand factor (VWF) and fibrinogen content. Arterial platelet deposition (×106/cm2) was reduced >80 {\%} by lamifiban (398 ± 437) compared to controls (1,540 ± 883; p < 0.005). Lamifiban also reduced venous thrombus platelet deposition (139 ± 88 vs. 281 ± 167) however did not prevent thrombosis. In control animals, venous stent platelet deposition correlated with plasma fibrinogen content (R2 = 0.29; p = 0.03). Fibrinogen content correlated directly with venous stent platelet deposition (p = 0.03) but not thrombus weight. Neither venous platelet deposition nor thrombus weights varied by VWF content. Platelet recruitment to venous stent thrombi occurs in part through the integrin αIIbβ3 receptor. Unlike arterial thrombosis, inhibition of this receptor is insufficient to prevent venous stent thrombosis.",
keywords = "GP IIb/IIIa, Integrin αIIbβ3, Lamifiban, Platelets, Venous stent thrombosis",
author = "McBane, {Robert D.} and Krzysztof Karnicki and Wysokinski, {Waldemar E.}",
year = "2013",
month = "11",
doi = "10.1007/s11239-013-0924-x",
language = "English (US)",
volume = "36",
pages = "442--447",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Platelet recruitment to venous stent thrombi

AU - McBane, Robert D.

AU - Karnicki, Krzysztof

AU - Wysokinski, Waldemar E.

PY - 2013/11

Y1 - 2013/11

N2 - Thrombosis following venous stent placement is a morbid clinical outcome. Whether to target platelets or coagulation factors for venous stent thromboprophylaxis remains unclear. We sought to determine whether integrin αIIbβ3 antagonism with lamifiban would inhibit platelet recruitment to venous stent thrombosis. Anti-thrombotic efficacy was compared between venous and arterial circulations. Pigs received either lamifiban (0.2 mg/kg bolus plus 0.2 mg/kg/h infusion; n = 6) or saline (n = 12). Carotid arteries were crush injured and then harvested 30 min later to provide an assessment of antithrombotic efficacy in the arterial circulation. Iliac venous stents were then deployed and thrombi allowed to propagate for 2 h before harvesting. Platelet deposition was measured by scintillation detection of autologous 111In-platelets. Venous thrombi were quantified by weight and compared to platelet, Von Willebrand factor (VWF) and fibrinogen content. Arterial platelet deposition (×106/cm2) was reduced >80 % by lamifiban (398 ± 437) compared to controls (1,540 ± 883; p < 0.005). Lamifiban also reduced venous thrombus platelet deposition (139 ± 88 vs. 281 ± 167) however did not prevent thrombosis. In control animals, venous stent platelet deposition correlated with plasma fibrinogen content (R2 = 0.29; p = 0.03). Fibrinogen content correlated directly with venous stent platelet deposition (p = 0.03) but not thrombus weight. Neither venous platelet deposition nor thrombus weights varied by VWF content. Platelet recruitment to venous stent thrombi occurs in part through the integrin αIIbβ3 receptor. Unlike arterial thrombosis, inhibition of this receptor is insufficient to prevent venous stent thrombosis.

AB - Thrombosis following venous stent placement is a morbid clinical outcome. Whether to target platelets or coagulation factors for venous stent thromboprophylaxis remains unclear. We sought to determine whether integrin αIIbβ3 antagonism with lamifiban would inhibit platelet recruitment to venous stent thrombosis. Anti-thrombotic efficacy was compared between venous and arterial circulations. Pigs received either lamifiban (0.2 mg/kg bolus plus 0.2 mg/kg/h infusion; n = 6) or saline (n = 12). Carotid arteries were crush injured and then harvested 30 min later to provide an assessment of antithrombotic efficacy in the arterial circulation. Iliac venous stents were then deployed and thrombi allowed to propagate for 2 h before harvesting. Platelet deposition was measured by scintillation detection of autologous 111In-platelets. Venous thrombi were quantified by weight and compared to platelet, Von Willebrand factor (VWF) and fibrinogen content. Arterial platelet deposition (×106/cm2) was reduced >80 % by lamifiban (398 ± 437) compared to controls (1,540 ± 883; p < 0.005). Lamifiban also reduced venous thrombus platelet deposition (139 ± 88 vs. 281 ± 167) however did not prevent thrombosis. In control animals, venous stent platelet deposition correlated with plasma fibrinogen content (R2 = 0.29; p = 0.03). Fibrinogen content correlated directly with venous stent platelet deposition (p = 0.03) but not thrombus weight. Neither venous platelet deposition nor thrombus weights varied by VWF content. Platelet recruitment to venous stent thrombi occurs in part through the integrin αIIbβ3 receptor. Unlike arterial thrombosis, inhibition of this receptor is insufficient to prevent venous stent thrombosis.

KW - GP IIb/IIIa

KW - Integrin αIIbβ3

KW - Lamifiban

KW - Platelets

KW - Venous stent thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84889079885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889079885&partnerID=8YFLogxK

U2 - 10.1007/s11239-013-0924-x

DO - 10.1007/s11239-013-0924-x

M3 - Article

C2 - 23595514

AN - SCOPUS:84889079885

VL - 36

SP - 442

EP - 447

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 4

ER -